Adherence to medication is a more important contributor to viral breakthrough in chronic hepatitis B patients treated with entecavir than in those with lamivudine

International Journal of Medical Sciences

Volumn 10, Issue 5, 2013, Pages 567-574

  Kamezaki, Hidehiro ^a   Kanda, Tatsuo ^a   Arai, Makoto ^a   Wu, Shuang ^a   Nakamoto, Shingo ^a   Chiba, Tetsuhiro ^a   Maruyama, Hitoshi ^a   Fujiwara, Keiichi ^a   Kanai, Fumihiko ^a   Imazeki, Fumio ^a   Nomura, Fumio ^a   Yokosuka, Osamu ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Adherence; Entecavir; Hepatitis B; Lamivudine; Viral breakthrough

Indexed keywords

ENTECAVIR; LAMIVUDINE;

ADULT; ANTIGEN DETECTION; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PATIENT COMPLIANCE; PHYSICAL EXAMINATION; RETROSPECTIVE STUDY; REVIEW; VIRUS MUTATION; VIRUS REACTIVATION; VIRUS RESISTANCE;

ADHERENCE; ENTECAVIR; HEPATITIS B; LAMIVUDINE; VIRAL BREAKTHROUGH.;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; GUANINE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MEDICATION ADHERENCE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84875296320     PISSN: 14491907     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijms.5795     Document Type: Review

References (27)

1. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007; 45: 507-539
2. Wu S, Fukai K, Imazeki F, et al. Initial virological response and viral mutation with adefovir dipivoxil added to ongoing Lamivudine therapy in Lamivudine-resistant chronic hepatitis B. Dig Dis Sci. 2011; 56: 1207-1214
3. Dienstag JL, Perrillo RP, Schiff ER, et al. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med. 1995; 333: 1657-1661
4. Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med. 1998;339:61-8
5. Innaimo SF, Seifer M, Bisacchi GS, et al. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother. 1997; 41: 1444-1448
6. Ono SK, Kato N, Shiratori Y, et al. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest. 2001; 107: 449-455
7. Hashimoto Y, Suzuki F, Hirakawa M, et al. Clinical and virological effects of long-term (over 5 years) lamivudine therapy. J Med Virol. 2010; 824: 684-691
8. Chotiyaputta W, Peterson C, Ditah FA, et al. Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B. J Hepatol. 2011; 54: 12-8
9. Ha NB, Ha NB, Garcia RT, et al. Medication nonadherence with long-term management of patients with hepatitis B e antigen-negative chronic hepatitis B. Dig Dis Sci. 2011; 56: 2423-31
10. Kamezaki H, Kanda T, Wu S, et al. Emergence of entecavir-resistant mutations in nucleos(t)ide-naive Japanese patients infected with hepatitis B virus: virological breakthrough is also dependent on adherence to medication. Scand J Gastroenterol. 2011; 46: 1111-1117
11. Haynes RB, McDonald HP, Garg AX. Helping patients follow prescribed treatment: clinical applications. JAMA. 2002; 288: 2880-2883
12. Bramley TJ, Gerbino PP, Nightengale BS, et al. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manag Care Pharm. 2006; 12: 239-245
13. Ishibashi H, Maruyama H, Takahashi M, et al. Assessment of hepatic fibrosis by analysis of the dynamic behaviour of microbubbles during contrast ultrasonography. Liver Int 2010; 30: 1355-1363
14. Wu S, Kanda T, Imazeki F, et al. Hepatitis B virus e antigen downregulates cytokine production in human hepatoma cell lines. Viral Immunol. 2010; 23: 467-476
15. Usuda S, Okamoto H, Iwanari H, et al. Serological detection of hepatitis B virus genotypes by ELISA with monoclonal antibodies to type-specific epitopes in the preS2-region product. J Virol Methods. 1999; 80: 97-112
16. Kobayashi S, Shimada K, Suzuki H, et al. Development of a new method for detecting a mutation in the gene encoding hepatitis B virus reverse transcriptase active site (YMDD motif). Hepatol Res. 2000; 17: 31-42
17. Kanda T, Jeong SH, Imazeki F, et al. Analysis of 5' nontranslated region of hepatitis A viral RNA genotype I from South Korea: comparison with disease severities. PLoS One. 2010; 5: e15139
18. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005; 352: 2682-2695
19. Chan HL, Leung NW, Hui AY, et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon- α2b and lamivudine with lamivudine alone. Ann Intern Med. 2005; 142: 240-250
20. Liaw YF, Jia JD, Chan HL, et al. Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C. Hepatology. 2011; 54: 1591-1599
21. Buster EH, Flink HJ, et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon α-2b. Gastroenterology. 2008; 135: 459-467
22. Wong VW, Wong GL, Yan KK, et al. Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2010; 51: 1945-1953
23. Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2004; 351: 1206-1217
24. Papadopoulous VP, Chrysagis DN, Protopapas AN, et al. Peginterferon alfa-2b as monotherapy or in combination with lamibudine in patients with HBeAg-negative chronic hepatitis B: a randomised study. Med Sci Monit. 2009; 15: CR56-CR61
25. Marcellin P, Bonino F, Lau GK, et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha- 2a. Gastroenterology. 2009; 136: 2169-2179
26. Liu H, Golin CE, Miller LG, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med. 2001; 134: 968-977
27. Zoutendijk R, Reijnders JG, Brown A, et al. Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naïve patients with a partial virological response. Hepatology. 2011; 54: 443-451.